Infosys Asked To Pay Ex-CFO Over Rs 12 Crore As Severance: 10 Points
- "While the award acknowledges that Infosys had bona fide disputes, its' counter claim for refund of previously paid severance amount of Rs. 5.2 crores and damages, has been rejected," Infosys said in a regulatory filing with the Bombay Stock Exchange (BSE).
- The arbitral award, however, is confidential, said Infosys, the country's second largest IT services exporter.
- Infosys will take legal advice for necessary actions to be undertaken in respect of the award, it said.
- Infosys shares ended at Rs 719.15, down Rs 7.40 or 1.02 per cent on the BSE.
- The severance package of Mr Bansal, who resigned as CFO in 2015 - amounted to Rs. 17.38 crore, equal to 24 months of pay.
- Out of the total Rs 17.38 crore, Infosys paid Mr Bansal Rs. 5 crore only. The subsequent payments were suspended after Mr Murthy and others objected to the severance package, terming it as excessive and that that it could be seen as "hush money".
- Mr Bansal then dragged Infosys to arbitration to claim the remaining Rs 12 crore. The company had said at the time that the payment includes non-compete obligation, including other rights and obligations.
- Mr Murthy had repeatedly raised issues of corporate governance at the company that he co-founded while it was being headed for the first time by an outsider - Mr Sikka.
- This ultimately led to an abrupt exit of Mr Sikka after a prolonged standoff with Infosys' promoters.
- Co-founder Nandan Nilekani then assumed charge as the non-executive chairman of Infosys in August 2017. Salil Parekh, a former Capgemini executive, succeeded Mr Sikka as the managing director and CEO of Infosys in January this year. (With inputs from agencies)
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
